Administered as an injectable or oral rapid dissolve tablet (RDT)
All preparation and handling equipment should be sterile and properly maintained to reduce the risk of contamination or compromised results
Obesity and associated insulin resistance are accompanied by increased oxidative stress in endothelial cells, during which the production of reactive oxygen species (ROS) surpasses the capacity of antioxidant factors to balance them
This allows the peptide to go straight to work without being broken down by your stomach acids
Observed effects in human trials Reported adverse events across the IV and oral trials included headache, fatigue, dizziness, nasopharyngitis, diarrhea, flatulence, increased appetite, nausea, and back pain
MOTS-C has been shown to reverse these age-related metabolic changes by improving insulin sensitivity and promoting cellular energy production